Final Programme - iuphar

More documents

Recommendations

Info

FC18 Nuclear receptor targets for treatment of diseases Thu 433 In silico approach to develop new selective PPARγ modulators (SPPARMs) Francesca Mancini, (Italy), M Vitiello, G Mangano, G Pochetti, MA Alisi, R Ombrato, E Fioravanzo, N Cazzolla, L Polenzani Thu 434 Peroxisome proliferator-activated receptor (PPAR) agonists protect podocytes from human kidney against cell death induced by oxygen/glucose deprivation-reoxygenation Gianluca Miglio, (Italy), AC Rosa, L Rattazzi, R Fantozzi Thu 435 Analysis of glucocorticoid receptor gene haplotype structure and its influence on disease activity and steroid therapy outcome in inflammatory bowel disease patients Jessica Mwinyi, (Switzerland), C Wenger, JJ Eloranta, GA Kullak-Ublick Thu 436 Influence of LHRH on sex hormone receptors in the CA3 of hippocampi of the male rat Bojana Petrovic, (Republic of Serbia), Z Zoric, D Drekic Thu 437 Inhibition of leukocyte endothelial cells interactions by activation of retinoid X receptor Laura Piqueras, (Spain), E Morcillo, C Company, J Cortijo, MJ Sanz Thu 438 Comparative analysis of gene regulation by the transcription factor PPARá between mouse and human Maryam Rakhshandehroo, (The Netherlands), G Hooiveld, M Müller, S Kersten Thu 439 Interaction between peroxisome proliferator-activated receptor-α and NADPH oxidases plays an important role in the development of pressure-overload cardiac hypertrophy Emma Robinson, (UK), DJ Grieve Thu 440 The fat-induced satiety factor OEA suppresses feeding through central release of oxytocin Adele Romano, (Italy), S Gaetani, J Fu, T Cassano, P Dipasquale, L Righetti, S Cianci, L Laconca, E Giannini, S Scaccianoce, D Piomelli, V Cuomo Thu 441 Renal side effects of short-term dexamethasone treatment Ita Samarzija, (Croatia) Thu 442 Activation of liver X receptors (α and β) by HIV protease inhibitors atazanavir and ritonavir and inhibition by non-nucleoside reverse transcriptase inhibitor efavirenz Jenny Svard, (Ireland), JP Spiers, F Mulcahy, M Hennessy Thu 443 Expression of the receptor for advanced glycation end products (RAGE) and high mobility group box 1 (HMGB1) is related to human dental pulpitis progression Salunya Tancharoen, (Thailand), T Tengrungsun, T Suddhasthira Thu 444 Bag1 regulates chaperone-mediated triage decisions on degradation of chronic myelogenous leukemia oncoprtein, BCR-ABL Fujiko Tsukahara, (Japan), Y Maru Thu 445 Neuroprotection of ginsenoside Rg1 against Aβ25-35-induced neurotoxicity in primary cultured rat cortical neurons via nuclear steroid receptors activation Jiang Wu, (PR China), Z Wang, X Zhang, W Zhu, Y Shen, R Cui, J Lin, Y Su, Y Lou 312 Thursday 22 July ■ 13:00 - 14:00 ■ Poster Area
Index The index shows the presentation reference for all authors and co-authors WorldPharma2010 provides a very large number of bursaries for young scientists from lesser developed countries Professor Zhi-Bin Lin (PR China) President of the 15th World Congress on Pharmacology (Beijing, 2006) Index 313
Page 1:
of basic and clinical pharmacology
Page 4 and 5:
Congress patron 2 HRH Crown Princes
Page 6 and 7:
Congress President Kim Brøsen Secr
Page 8 and 9:
General information Registration &
Page 10 and 11:
Banks, currency & credit cards The
Page 12 and 13:
Information to presenters ■ The a
Page 14 and 15:
Hotel Bella Center Copenhagen Groun
Page 16 and 17:
Programme at a glance Time Hall A2
Page 18 and 19:
16 General events General events Op
Page 20 and 21:
Programme outline Plenary lectures
Page 22 and 23:
FC10 Drugs for half the world: Paed
Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
Page 26 and 27:
W01 Pharmacology of adrenoceptors:
Page 28 and 29:
W02 Symposium on advances in GI pha
Page 30 and 31:
W04 Symposium: Antioxidants as ther
Page 32 and 33:
Plenary lectures PL01 Plenary lectu
Page 34 and 35:
FC02 Transmembrane transport: Persp
Page 36 and 37:
FC04 Pharmacoepidemiology, current
Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
Page 40 and 41:
FC09 Inflammation and immunopharmac
Page 42 and 43:
Page 44 and 45:
SS01 Sponsored symposium Sponsored
Page 46 and 47:
W06 Workshop. Effect of disease on
Page 48 and 49:
W08 Workshop. Identifying targets f
Page 50 and 51:
W10 Workshop. Innovative Medicines
Page 52 and 53:
FC01 Clinical pharmacology in the e
Page 54 and 55:
FC03 Ion channels in analgesia and
Page 56 and 57:
FC05 Translational science in the m
Page 58 and 59:
Page 60 and 61:
FC08 Development in the treatment o
Page 62 and 63:
Plenary lectures PL04 Plenary lectu
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
FC07 Simulation and data modelling
Page 72 and 73:
Page 74 and 75:
W12 Workshop. Experimental pain met
Page 76 and 77:
W14 Workshop. Translating the human
Page 78 and 79:
W15 Workshop. The IUPHAR initiative
Page 80 and 81:
W17 Workshop. Standards for PhD Edu
Page 82 and 83:
W19 Workshop. Influence of degenera
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
FC08 Development in the treatment o
Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
Page 94 and 95:
Page 96 and 97:
FC12 Ion channelopathies: New windo
Page 98 and 99:
FC14 Addiction and doping: Neurobio
Page 100 and 101:
FC17 New approaches and targets in
Page 102 and 103:
W04 Symposium: Antioxidants as ther
Page 104 and 105:
W21 Workshop. Inflammation - here,
Page 106 and 107:
W23 Workshop. Applying pharmacogeno
Page 108 and 109:
W25 Workshop. High science in the l
Page 110 and 111:
W27 Workshop. Approaches to medicin
Page 112 and 113:
FC11 G protein-coupled 7TM receptor
Page 114 and 115:
FC13 Maximising benefits and minimi
Page 116 and 117:
FC15 Endothelium in Health and dise
Page 118 and 119:
Page 120 and 121:
FC18 Nuclear receptor targets for t
Page 122 and 123:
PL16 Plenary Lecture Supported by a
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
FC15 Endothelium in Health and dise
Page 130 and 131:
Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
Page 134 and 135:
W30 Workshop. Is eNOS still a valid
Page 136 and 137:
W32 Workshop. The good, the bad and
Page 138 and 139:
W34 Workshop. State-of-the-art of b
Page 140 and 141:
FC10 Drugs for half the world: Pedi
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
FC16 Natural products: Past and fut
Page 148 and 149:
FC18 Nuclear receptor targets for t
Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
FC15 Endothelium in health and dise
Page 158 and 159:
Page 160 and 161:
158
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
W12 Experimental pain methods in de
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
FC06 The heart gone wrong; stabiliz
Page 180 and 181:
Page 182 and 183:
FC08 Developments in the treatment
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
W03 Targeting TRP channels for pain
Page 196 and 197:
W19 Influence of degeneration and r
Page 198 and 199:
W19 Influence of degeneration and r
Page 200 and 201:
W20 Pharmacology education for a su
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
FC06 The heart gone wrong; stabiliz
Page 216 and 217:
Page 218 and 219:
FC08 Developments in the treatment
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
FC19 General session Tue 361 Analge
Page 232 and 233:
FC19 General session - Biologics Tu
Page 234 and 235:
FC19 General session - Haematology
Page 236 and 237:
FC19 General session - oncology Tue
Page 238 and 239:
FC19 General session - oncology Tue
Page 240 and 241:
FC19 General session - Toxicology T
Page 242 and 243:
Page 244 and 245:
W11 New opportunities in the pharma
Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
FC15 Endothelium in health and dise
Page 264 and 265: FC15 Endothelium in health and dise
Page 268 and 269: W30 Is eNOS Still a valid therapeut
Page 270 and 271: FC16 Natural products: Past and fut
Page 276 and 277: FC17 New approaches and targets in
Page 280 and 281: W34 State-of-the-art of basic and c
Page 282 and 283: FC10 Drugs for half the world: Paed
Page 284 and 285: FC11 G protein-coupled 7TM receptor
Page 290 and 291: FC13 Maximising benefits and minimi
Page 292 and 293: FC13 Maximising benefits and minimi
Page 294 and 295: W29 New horizons in therapeutic dru
Page 296 and 297: FC14 Addiction and doping: Neurobio
Page 316 and 317: 314 Index Name Paper ref. Name Pape
Page 364 and 365:
362 Index Name Paper ref. Name Pape
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
382 Notes Notes
Page 386:
Final Programme printed in Singapor
show all

Final Programme - iuphar

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?